EDESA BIOTECH, INC. Increase (Decrease) in Deferred Revenue
EDESA BIOTECH, INC. (EDSA) reported Increase (Decrease) in Deferred Revenue of $0 for the 3-month period ending 2016-12-31, per its 10-Q filed 2017-02-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2017-12-01
- EDESA BIOTECH, INC. increase (decrease) in deferred revenue for the quarter ending 2016-12-31 was $0.00.
- EDESA BIOTECH, INC. increase (decrease) in deferred revenue for the quarter ending 2016-09-30 was -$173.33K.
- EDESA BIOTECH, INC. increase (decrease) in deferred revenue for the quarter ending 2016-06-30 was $0.00, a 100.00% decline year-over-year.
- EDESA BIOTECH, INC. increase (decrease) in deferred revenue for the quarter ending 2016-03-31 was $173.33K.
- EDESA BIOTECH, INC. increase (decrease) in deferred revenue for fiscal 2016 was -$173.33K, a 300.00% decline from fiscal 2015.
- EDESA BIOTECH, INC. increase (decrease) in deferred revenue for fiscal 2015 was $86.67K, a 477.77% increase from fiscal 2014.
- EDESA BIOTECH, INC. increase (decrease) in deferred revenue for fiscal 2014 was $15.00K.
- EDESA BIOTECH, INC. increase (decrease) in deferred revenue for fiscal 2013 was -$127.48K, a 200.00% decline from fiscal 2012.
| Period end | Increase (Decrease) in Deferred Revenue 1 month | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|---|
| 2016-12-31 | $0.00 10-Q · filed 2017-02-06 | -$173.33K derived: sum of 2 quarters · filed 2017-12-01 | -$173.33K derived: sum of 3 quarters · filed 2017-12-01 | $0.00 derived: sum of 4 quarters · filed 2017-12-01 | |
| 2016-09-30 | -$173.33K derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-01 | -$173.33K derived: sum of 2 quarters · filed 2017-12-01 | $0.00 derived: sum of 3 quarters · filed 2017-12-01 | -$173.33K 10-K · filed 2017-12-01 | |
| 2016-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-09 | $173.33K derived: sum of 2 quarters · filed 2016-08-09 | $0.00 10-Q · filed 2016-08-09 | $0.00 derived: sum of 4 quarters · filed 2017-12-01 | |
| 2016-03-31 | $173.33K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-09 | $0.00 10-Q · filed 2016-05-09 | $0.00 derived: sum of 3 quarters · filed 2017-12-01 | $173.33K derived: sum of 4 quarters · filed 2017-12-01 | |
| 2015-12-31 | -$173.33K 10-Q · filed 2017-02-06 | -$173.33K derived: sum of 2 quarters · filed 2017-12-01 | $0.00 derived: sum of 3 quarters · filed 2017-12-01 | -$86.67K derived: sum of 4 quarters · filed 2017-12-01 | |
| 2015-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-01 | $173.33K derived: sum of 2 quarters · filed 2017-12-01 | $86.67K derived: sum of 3 quarters · filed 2017-12-01 | $86.67K 10-K · filed 2017-12-01 | |
| 2015-06-30 | $173.33K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-09 | $86.67K derived: sum of 2 quarters · filed 2016-08-09 | $86.67K 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | -$86.67K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-09 | -$86.67K 10-Q · filed 2016-05-09 | |||
| 2014-12-31 | $0.00 10-Q · filed 2016-02-08 | ||||
| 2014-09-30 | $71.67K 10-K · filed 2016-12-14 | ||||
| 2014-08-31 | $15.00K 10-K · filed 2016-12-14 | ||||
| 2013-08-31 | -$127.48K 10-K · filed 2015-12-14 | ||||
| 2012-08-31 | $127.48K 10-K · filed 2014-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |